EA202091056A1 - Направленная замена эндогенных т-клеточных рецепторов - Google Patents

Направленная замена эндогенных т-клеточных рецепторов

Info

Publication number
EA202091056A1
EA202091056A1 EA202091056A EA202091056A EA202091056A1 EA 202091056 A1 EA202091056 A1 EA 202091056A1 EA 202091056 A EA202091056 A EA 202091056A EA 202091056 A EA202091056 A EA 202091056A EA 202091056 A1 EA202091056 A1 EA 202091056A1
Authority
EA
Eurasian Patent Office
Prior art keywords
endogenic
cell receptors
targeted replacement
tcr
strand
Prior art date
Application number
EA202091056A
Other languages
English (en)
Russian (ru)
Inventor
Теодор Ли Рот
Эрик Шифрут
Александр Марсон
Кристина Пюиг Сос
Энтони Рибас
Original Assignee
Те Риджентс Оф Те Юниверсити Оф Калифорния
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Те Риджентс Оф Те Юниверсити Оф Калифорния filed Critical Те Риджентс Оф Те Юниверсити Оф Калифорния
Publication of EA202091056A1 publication Critical patent/EA202091056A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EA202091056A 2017-10-27 2018-10-29 Направленная замена эндогенных т-клеточных рецепторов EA202091056A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762578153P 2017-10-27 2017-10-27
PCT/US2018/058026 WO2019084552A1 (en) 2017-10-27 2018-10-29 TARGETED REPLACEMENT OF ENDOGENIC T CELL RECEPTORS

Publications (1)

Publication Number Publication Date
EA202091056A1 true EA202091056A1 (ru) 2020-09-17

Family

ID=66247037

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091056A EA202091056A1 (ru) 2017-10-27 2018-10-29 Направленная замена эндогенных т-клеточных рецепторов

Country Status (13)

Country Link
US (6) US11033584B2 (enExample)
EP (1) EP3700924A4 (enExample)
JP (3) JP7101419B2 (enExample)
KR (2) KR102770787B1 (enExample)
CN (2) CN118581047A (enExample)
AU (2) AU2018355587B2 (enExample)
CA (1) CA3080415A1 (enExample)
EA (1) EA202091056A1 (enExample)
IL (2) IL305485B2 (enExample)
MX (1) MX2020004325A (enExample)
MY (1) MY201694A (enExample)
SG (1) SG11202003798TA (enExample)
WO (1) WO2019084552A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3638317A4 (en) 2017-06-15 2021-03-17 The Regents of The University of California TARGETED NONVIRAL DNA INSERTIONS
KR102770787B1 (ko) 2017-10-27 2025-02-19 더 리전트 오브 더 유니버시티 오브 캘리포니아 내인성 t 세포 수용체의 표적화된 대체
CN111918659B (zh) 2017-10-30 2024-01-30 派克特制药公司 原代细胞基因编辑
WO2019195310A1 (en) 2018-04-02 2019-10-10 Pact Pharma, Inc. Peptide-mhc compacts
CA3095084A1 (en) * 2018-04-05 2019-10-10 Juno Therapeutics, Inc. T cells expressing a recombinant receptor, related polynucleotides and methods
WO2019226998A1 (en) * 2018-05-25 2019-11-28 The Regents Of The University Of California Genetic engineering of endogenous proteins
KR20210126073A (ko) 2019-02-12 2021-10-19 팩트 파마, 인크. 항원 특이적 t 세포의 식별을 위한 조성물 및 방법
AU2020325225A1 (en) * 2019-08-05 2022-03-24 Cartherics Pty. Ltd. Immune cells expressing modified cell receptors and methods of making
EP3808765A1 (en) * 2019-10-14 2021-04-21 ETH Zurich Cell line for tcr discovery and engineering and methods of use thereof
CN114901812A (zh) * 2019-11-14 2022-08-12 国立大学法人广岛大学 使用环状dna将抗原特异性受体基因导入至t细胞基因组的方法
KR20230036059A (ko) * 2020-03-13 2023-03-14 더 리전트 오브 더 유니버시티 오브 캘리포니아 표적 핵산을 변형시키는 조성물 및 방법
AU2021332334A1 (en) * 2020-08-27 2023-05-04 Tmunity Therapeutics Inc. Vector-free process for manufacture of engineered immune cells
JP2023544161A (ja) * 2020-10-02 2023-10-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア がんの改善されたｔ細胞免疫療法のためのｄｎａ構築物
PE20241173A1 (es) 2021-10-14 2024-05-28 Arsenal Biosciences Inc Celulas inmunitarias que tienen arnhc coexpresados y sistemas de compuerta logica
US20250382340A1 (en) * 2022-02-14 2025-12-18 The Regents Of The University Of California Dna constructs for improved t cell immunotherapy
CA3265658A1 (en) 2022-09-13 2024-03-21 Arsenal Biosciences, Inc. IMMUNE CELLS POSSESSING CO-EXPRESSED TGFBR SHRNA
CN119968464A (zh) 2022-09-16 2025-05-09 阿森纳生物科学公司 具有组合基因扰动的免疫细胞
WO2024130179A1 (en) 2022-12-16 2024-06-20 Repertoire Immune Medicines, Inc. T cell receptors binding hpv-16 epitopes
WO2024163935A2 (en) * 2023-02-03 2024-08-08 Affini-T Therapeutics, Inc. Host cells bearing kras binding protein and knockout of endogenous tcr and methods of use thereof
AU2024228388A1 (en) 2023-02-27 2025-10-02 Adaptive Biotechnologies Corp. Therapeutic t cell receptors targeting kras g12d
WO2024186656A1 (en) 2023-03-03 2024-09-12 Arsenal Biosciences, Inc. Systems targeting psma and ca9
TW202436346A (zh) 2023-03-13 2024-09-16 美商亞森諾生物科學公司 合成路徑活化劑
WO2025193663A2 (en) * 2024-03-11 2025-09-18 Affini-T Therapeutics, Inc. Compositions and methods for treating neoplasia
WO2025199346A1 (en) 2024-03-20 2025-09-25 Arsenal Biosciences, Inc. Antigen binding proteins that bind tmprss4 and methods of use thereof
US20250297255A1 (en) 2024-03-20 2025-09-25 Arsenal Biosciences, Inc. Systems targeting tmprss4 and slc34a2

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6773669B1 (en) 1995-03-10 2004-08-10 Maxcyte, Inc. Flow electroporation chamber and method
US6090617A (en) 1996-12-05 2000-07-18 Entremed, Inc. Flow electroporation chamber with electrodes having a crystalline metal nitride coating
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
AU5574801A (en) 2000-04-28 2001-11-12 Sangamo Biosciences Inc Methods for binding an exogenous molecule to cellular chromatin
US7029916B2 (en) 2001-02-21 2006-04-18 Maxcyte, Inc. Apparatus and method for flow electroporation of biological samples
DE10291734D2 (de) 2001-04-23 2004-05-27 Lorbach Elke Pufferlösung für die Elektroporation und Verfahren umfassend die Verwendung derselben
US7141425B2 (en) 2001-08-22 2006-11-28 Maxcyte, Inc. Apparatus and method for electroporation of biological samples
GB0124391D0 (en) 2001-10-11 2001-11-28 Gene Expression Technologies L Control of gene expression
US20050136040A1 (en) 2001-10-11 2005-06-23 Imperial College Innovations Limited Control of gene expression using a complex of an oligonucleotide and a regulatory peptide
EP1504092B2 (en) 2002-03-21 2014-06-25 Sangamo BioSciences, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
ITMI20030821A1 (it) 2003-04-18 2004-10-19 Internat Ct For Genetic En Gineering And Polipeptidi chimerici e loro uso.
WO2004108883A2 (en) 2003-06-10 2004-12-16 Toolgen, Inc. Transducible dna-binding proteins
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
ES2294757T3 (es) 2004-03-15 2008-04-01 Amaxa Ag Recipiente y dispositivo para generar campos electricos en espacios de reaccion individuales.
WO2005113820A2 (en) 2004-05-12 2005-12-01 Maxcyte, Inc. Methods and devices related to a regulated flow electroporation chamber
US8932850B2 (en) 2004-06-12 2015-01-13 Invitrogen Singapore Pte. Ltd. Electroporation apparatus having an elongated hollow member
ES2465467T3 (es) 2004-06-14 2014-06-05 Lonza Cologne Ag Procedimiento y disposición de circuito para el tratamiento de material biológico
WO2005123962A2 (en) 2004-06-14 2005-12-29 The University Of Texas At Austin Gene targeting in eukaryotic cells by group ii intron ribonucleoprotein particles
KR20070091163A (ko) 2004-11-30 2007-09-07 맥스시티 인코포레이티드 컴퓨터화된 일렉트로포레이션
US10022457B2 (en) 2005-08-05 2018-07-17 Gholam A. Peyman Methods to regulate polarization and enhance function of cells
EP3284833B1 (en) 2005-08-26 2021-12-01 DuPont Nutrition Biosciences ApS Use of crispr associated genes (cas)
EP2395081A1 (en) 2006-08-11 2011-12-14 Dow AgroSciences LLC Zinc finger nuclease-mediated homologous recombination
WO2009126789A2 (en) 2008-04-09 2009-10-15 Maxcyte, Inc. Engineering and delivery of therapeutic compositions of freshly isolated cells
DK2310500T3 (en) 2008-07-18 2015-05-11 Maxcyte Inc Process for optimizing electroporation
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
JP2012525146A (ja) 2009-04-28 2012-10-22 プレジデント アンド フェロウズ オブ ハーバード カレッジ 細胞透過のための過剰に荷電されたタンパク質
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US8956828B2 (en) * 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
ES2696825T3 (es) 2009-12-10 2019-01-18 Univ Minnesota Modificación del ADN inducida por el efector TAL
CN102939377B (zh) 2010-04-26 2016-06-08 桑格摩生物科学股份有限公司 使用锌指核酸酶对Rosa位点进行基因组编辑
US8876458B2 (en) 2011-01-25 2014-11-04 United Technologies Corporation Blade outer air seal assembly and support
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
US20130236504A1 (en) 2012-03-06 2013-09-12 Medical University Of South Carolina Delivery System for Enhancing Drug Efficacy
MY189533A (en) 2012-05-25 2022-02-16 Univ California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
WO2014065596A1 (en) 2012-10-23 2014-05-01 Toolgen Incorporated Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
AU2013355214B2 (en) 2012-12-06 2017-06-15 Sigma-Aldrich Co. Llc Crispr-based genome modification and regulation
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
CA2894668A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas systems and methods for altering expression of gene products in eukaryotic cells
WO2014093701A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
EP4481048A3 (en) 2012-12-17 2025-02-26 President and Fellows of Harvard College Rna-guided human genome engineering
KR102210319B1 (ko) 2013-03-15 2021-02-01 더 제너럴 하스피탈 코포레이션 특정 게놈 좌위에 대한 유전적 및 후성적 조절 단백질의 rna-안내 표적화
AU2014232314B2 (en) * 2013-03-15 2020-05-14 Adaptive Biotechnologies Corporation Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set
JP6346266B2 (ja) * 2013-03-21 2018-06-20 サンガモ セラピューティクス， インコーポレイテッド 操作されたジンクフィンガータンパク質ヌクレアーゼを使用するｔ細胞受容体遺伝子の標的化された破壊
US20160053274A1 (en) 2013-04-02 2016-02-25 Bayer Cropscience Nv Targeted genome engineering in eukaryotes
EP3309248B1 (en) * 2013-05-29 2021-06-09 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
ES2883131T3 (es) 2013-05-29 2021-12-07 Cellectis Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
WO2015048690A1 (en) 2013-09-27 2015-04-02 The Regents Of The University Of California Optimized small guide rnas and methods of use
DK3441468T3 (da) 2013-10-17 2021-07-26 Sangamo Therapeutics Inc Afgivelsesfremgangsmåder og sammensætninger til nukleasemedieret genom-manipulation
WO2015073867A1 (en) 2013-11-15 2015-05-21 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Engineering neural stem cells using homologous recombination
WO2015089419A2 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
WO2015089486A2 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
KR20250068794A (ko) 2013-12-12 2025-05-16 더 브로드 인스티튜트, 인코퍼레이티드 게놈 편집을 위한 ｃｒｉｓｐｒ-ｃａｓ 시스템 및 조성물의 전달, 용도 및 치료적 응용
CA2933134A1 (en) 2013-12-13 2015-06-18 Cellectis Cas9 nuclease platform for microalgae genome engineering
US9770489B2 (en) 2014-01-31 2017-09-26 Factor Bioscience Inc. Methods and products for nucleic acid production and delivery
WO2015115903A1 (en) 2014-02-03 2015-08-06 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Site-specific dna break-induced genome editing using engineered nucleases
SG10201809157VA (en) 2014-04-18 2018-11-29 Editas Medicine Inc Crispr-cas-related methods, compositions and components for cancer immunotherapy
EP3188763B1 (en) 2014-09-02 2020-05-13 The Regents of The University of California Methods and compositions for rna-directed target dna modification
RU2017113134A (ru) * 2014-09-19 2018-10-19 Регенерон Фармасьютикалз, Инк. Химерные антигенные рецепторы
WO2016049251A1 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
EP3204513A2 (en) 2014-10-09 2017-08-16 Life Technologies Corporation Crispr oligonucleotides and gene editing
KR20170075013A (ko) 2014-10-31 2017-06-30 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Cart 세포에서 유전자 발현의 변경 및 그의 용도
WO2016097751A1 (en) 2014-12-18 2016-06-23 The University Of Bath Method of cas9 mediated genome engineering
AU2016209295B2 (en) 2015-01-21 2021-08-12 Genevant Sciences Gmbh Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells
EP3250693B2 (en) 2015-01-30 2023-12-20 The Regents of The University of California Protein delivery in primary hematopoietic cells
WO2016135559A2 (en) 2015-02-23 2016-09-01 Crispr Therapeutics Ag Materials and methods for treatment of human genetic diseases including hemoglobinopathies
US20180298340A1 (en) 2015-04-24 2018-10-18 The Regents Of The University Of California Systems for detecting, monitoring or treating diseases or conditions using engineered cells and methods for making and using them
US20180161368A1 (en) 2015-05-29 2018-06-14 Juno Therapeutics, Inc. Composition and methods for regulating inhibitory interactions in genetically engineered cells
US11643668B2 (en) 2015-06-17 2023-05-09 The Uab Research Foundation CRISPR/Cas9 complex for genomic editing
CA2989858A1 (en) 2015-06-17 2016-12-22 The Uab Research Foundation Crispr/cas9 complex for introducing a functional polypeptide into cells of blood cell lineage
US20170000743A1 (en) 2015-07-02 2017-01-05 Vindico NanoBio Technology Inc. Compositions and Methods for Delivery of Gene Editing Tools Using Polymeric Vesicles
AU2016291778B2 (en) 2015-07-13 2021-05-06 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
CA2996913A1 (en) 2015-09-01 2017-03-09 The Hospital For Sick Children Method and compositions for removing duplicated copy number variations (cnvs) for genetic disorders and related uses
CA2997749A1 (en) * 2015-09-09 2017-03-16 Immune Design Corp. Ny-eso-1 specific tcrs and methods of use thereof
WO2017053729A1 (en) 2015-09-25 2017-03-30 The Board Of Trustees Of The Leland Stanford Junior University Nuclease-mediated genome editing of primary cells and enrichment thereof
US11286480B2 (en) 2015-09-28 2022-03-29 North Carolina State University Methods and compositions for sequence specific antimicrobials
US10799535B2 (en) * 2015-10-05 2020-10-13 Precision Biosciences, Inc. Engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene
JP6816133B2 (ja) * 2015-10-05 2021-01-20 プレシジョン バイオサイエンシズ，インク． 改変ヒトｔ細胞受容体アルファ定常領域遺伝子を含む遺伝子改変細胞
EP3365269A4 (en) 2015-10-19 2019-06-19 The Methodist Hospital CRISPR-CAS9 DELIVERY TO HEAVY-TO-TRANSFECT CELLS THROUGH MEMBRANE FORMING
US20180312873A1 (en) 2015-10-20 2018-11-01 10X Genomics, Inc. Method and systems for high throughput single cell genetic manipulation
WO2017070429A1 (en) 2015-10-22 2017-04-27 Regents Of The University Of Minnesota Methods involving editing polynucleotides that encode t cell receptor
ES2953925T3 (es) 2015-11-04 2023-11-17 Fate Therapeutics Inc Ingeniería genómica de células pluripotentes
ES2930643T3 (es) 2015-11-23 2022-12-20 Univ California Seguimiento y manipulación de ARN celular a través de la administración nuclear de CRISPR/CAS9
WO2017106528A2 (en) * 2015-12-18 2017-06-22 Sangamo Biosciences, Inc. Targeted disruption of the t cell receptor
WO2017115128A2 (en) 2015-12-30 2017-07-06 Avectas Limited Vector-free delivery of gene editing proteins and compositions to cells and tissues
EP3426690A4 (en) * 2016-03-11 2019-10-09 Bluebird Bio, Inc. GENOMEDITIZED IMMUNEFFECTOR CELLS
JP2019510503A (ja) 2016-04-07 2019-04-18 ブルーバード バイオ， インコーポレイテッド キメラ抗原受容体ｔ細胞組成物
EP4166161A1 (en) 2016-04-14 2023-04-19 Fred Hutchinson Cancer Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
ES2933961T3 (es) * 2016-04-15 2023-02-15 Memorial Sloan Kettering Cancer Center Células T transgénicas y composiciones de células T de receptor de antígeno quimérico y métodos relacionados
WO2017189336A1 (en) 2016-04-25 2017-11-02 The Regents Of The University Of California Methods and compositions for genomic editing
DK3448990T5 (da) 2016-04-29 2021-09-27 Basf Plant Science Co Gmbh Fremgangsmåder til modifikation af målnukleinsyrer ved anvendelse af et fusionsmolekyle bestående af guide- og donor-dna, rna-fusionsmolekyle og vektorsystemer, der koder for rna-fusionsmolekylet
WO2017210334A1 (en) 2016-05-31 2017-12-07 Massachusetts Institute Of Technology Hydrodynamically controlled electric fields for high throughput transformation & high throughput parallel transformation platform
DK3472338T3 (da) 2016-06-20 2024-07-15 Octapharma Ag Midler og fremgangsmåder til at modifikation af flere alleler
CN110312799A (zh) 2016-08-17 2019-10-08 博德研究所 新型crispr酶和系统
US11999931B2 (en) 2016-08-20 2024-06-04 The Regents Of The University Of California High-throughput system and method for the temporary permeabilization of cells
EP3526235A4 (en) 2016-10-12 2021-03-10 Feldan Bio Inc. SYNTHETIC PEPTIDIC SHUTTLE AGENTS RATIONALLY DESIGNED TO DELIVER POLYPEPTIDIC CARGOS FROM EXTRACELLULAR SPACE TO CYTOSOL AND / OR TARGET EUKARYOTE CELL CORE, THEIR USES, METHODS AND ASSOCIATED KITS
WO2018073393A2 (en) 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
WO2018073391A1 (en) 2016-10-19 2018-04-26 Cellectis Targeted gene insertion for improved immune cells therapy
EP3541937A4 (en) 2016-11-18 2020-06-24 Christopher Bradley REPAIR OF MASSIVELY MULTIPLEXED HOMOLOGICAL TEMPLATE FOR FULL GENERATION
KR20210035022A (ko) 2016-12-14 2021-03-31 리간달 인코포레이티드 핵산 및/또는 단백질 적재물 전달을 위한 조성물 및 방법
EP3562594A4 (en) 2016-12-30 2020-09-09 The Regents of University of California PROCESSES FOR SELECTING AND GENERATING T-LYMPHOCYTES MODIFIED BY THE GENOME
EP3638317A4 (en) 2017-06-15 2021-03-17 The Regents of The University of California TARGETED NONVIRAL DNA INSERTIONS
KR102770787B1 (ko) * 2017-10-27 2025-02-19 더 리전트 오브 더 유니버시티 오브 캘리포니아 내인성 t 세포 수용체의 표적화된 대체
CN111918659B (zh) * 2017-10-30 2024-01-30 派克特制药公司 原代细胞基因编辑

Also Published As

Publication number Publication date
US20210228631A1 (en) 2021-07-29
KR102770787B1 (ko) 2025-02-19
US11331346B2 (en) 2022-05-17
WO2019084552A1 (en) 2019-05-02
EP3700924A1 (en) 2020-09-02
JP2021500889A (ja) 2021-01-14
IL305485A (en) 2023-10-01
SG11202003798TA (en) 2020-05-28
US11590171B2 (en) 2023-02-28
AU2018355587A1 (en) 2020-06-18
KR102503130B1 (ko) 2023-02-24
JP2024174943A (ja) 2024-12-17
US11083753B1 (en) 2021-08-10
US20210353678A1 (en) 2021-11-18
IL274179B2 (en) 2024-02-01
US20250361287A1 (en) 2025-11-27
KR20230034416A (ko) 2023-03-09
EP3700924A4 (en) 2021-11-03
IL274179A (en) 2020-06-30
CN118581047A (zh) 2024-09-03
AU2023202582A1 (en) 2023-05-18
JP2022137112A (ja) 2022-09-21
IL305485B2 (en) 2025-10-01
BR112020008201A2 (pt) 2020-10-06
US20200000851A1 (en) 2020-01-02
AU2018355587B2 (en) 2023-02-02
JP7101419B2 (ja) 2022-07-15
US11033584B2 (en) 2021-06-15
CA3080415A1 (en) 2019-05-02
US12398193B2 (en) 2025-08-26
MY201694A (en) 2024-03-13
MX2020004325A (es) 2020-11-09
IL305485B1 (en) 2025-06-01
KR20200088348A (ko) 2020-07-22
CN111655719A (zh) 2020-09-11
US20230310502A1 (en) 2023-10-05
IL274179B1 (en) 2023-10-01
US20220241336A1 (en) 2022-08-04

Similar Documents

Publication Publication Date Title
EA202091056A1 (ru) Направленная замена эндогенных т-клеточных рецепторов
GB2564823A (en) Compositions and methods for T-cell receptors reprogramming using fusion proteins
CY1124627T1 (el) Στοχευμενη τροποποιηση γονιδιωματος αρουραιου
DK3756682T3 (da) Genetisk modificerede celler, der omfatter et modificeret gen fra det konstante område af den humane t-cellereceptor alpha
MX2025003235A (es) Composiciones y metodos para el suministro de proteinas de membrana
ZA201708000B (en) Compositions and methods for tcr reprogramming using fusion proteins
CO2021006363A2 (es) Composiciones y métodos para la expresión de transgenes a partir de un locus de albúmina
MX2020011562A (es) Agonistas del receptor de la hormona tiroidea y usos de los mismos.
MA52781A (fr) Anticorps contre entpd2, polythérapies, et procédés d'utilisation des anticorps et des polythérapies
MX2024001190A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
EP3850647A4 (en) BATTERY ELECTRODE COMPOSITION WITH CARBON FROM BIOMASS
MX2021001009A (es) Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión específicas de la diana.
MX2020004043A (es) Composiciones y métodos para la edición génica de hemofilia a.
NZ737399A (en) Ccr2 modulators
EP3804741A3 (en) Selection methods for genetically-modified t cells
PH12019502576A1 (en) Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
MX2018015285A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MX2018015277A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
EP4497477A3 (en) Improved synthesis of the radiolabeled prostate-specific membrane antigen (psma) inhibitor [18f]dcfpyl
PH12016501689A1 (en) Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
MX2023011453A (es) Composiciones para usarse en el tratamiento y prevencion de degeneracion macular.
MX2021002225A (es) Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion.
IL292894A (en) Compositions for reprogramming cells into dendritic cells type 2 competent for antigen presentation, methods and uses thereof
PH12017502099A1 (en) Methods for diagnosing and assessing treatment for cushing's syndrome
EP3708125C0 (en) BACK TIP EXTENDER FOR PENILE IMPLANT